{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-8063245-leuprolide:v1","objectPathId":"pubmed-pmid-8063245-leuprolide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-8063245-leuprolide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8063245-leuprolide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8063245-leuprolide-v1.md"},"story":{"slug":"pubmed-pmid-8063245-leuprolide","version":1,"domain":"Literature metadata","dateInSource":"2013-11-21","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["leuprolide"],"peptides":[{"slug":"leuprolide","url":"https://peptidescanner.com/peptides/leuprolide/"}]},"claims":[{"id":"headline","text":"Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.","sourceIds":["pubmed-observation-pmid-8063245-2013-11-21-106e08f55429"]},{"id":"summary","text":"PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-8063245-2013-11-21-106e08f55429"]},{"id":"paragraph-1","text":"PubMed lists PMID 8063245 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1994-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-8063245-2013-11-21-106e08f55429"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-8063245-2013-11-21-106e08f55429"]}],"sources":[{"id":"pubmed-observation-pmid-8063245-2013-11-21-106e08f55429","name":"PubMed","sourceClass":"A","title":"Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. · retained source version 1:2013-11-21:current:106e08f55429b6e17db7a37aa400329bf9ea2a63b7acbe9451338a7ee6a76021","url":"https://pubmed.ncbi.nlm.nih.gov/8063245/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"1321c878afbe5527aa14239d0b8476db7268a65113f4fab7961a6d202c775aaf","tierARecordSha256":"1505c81e98c34e9bcdc87c1f16987e290201d25a7cf9572ca8a005fc3dfbc745"},"integrity":{"algorithm":"sha256","contentSha256":"3d6e4842b762e5b929a42bca4bf91fbd898e8318897de026198a9bc847ac5fb5"}}